Literature DB >> 20184928

Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice.

Myung Sook Huh1, Seung-Young Lee, Sangjin Park, Seulki Lee, Hyunjin Chung, Sojin Lee, Yongseok Choi, Yu-Kyoung Oh, Jae Hyung Park, Seo Young Jeong, Kuiwon Choi, Kwangmeyung Kim, Ick Chan Kwon.   

Abstract

Here, we designed a new nano-sized siRNA carrier system composed of biocompatible/biodegradable glycol chitosan polymer (GC) and strongly positively charged polyethylenimine (PEI) polymers. In order to make a stable and tumor-homing nano-sized carrier, each polymer was modified with hydrophobic 5beta-cholanic acid, and they were simply mixed to form self-assembled GC-PEI nanoparticles (GC-PEI NPs), due to the strong hydrophobic interactions of 5beta-cholanic acids in the polymers. The freshly prepared GC-PEI NPs showed a stable nanoparticle structure (350nm) and they presented a strongly positive-charged surface (zeta potential=23.8) that is enough to complex tightly with negatively charged RFP-siRNAs, designed for inhibiting red fluorescent protein (RFP) expression. The siRNA encapsulated nanoparticles (siRNA-GC-PEI NPs) formed more compact and stable nanoparticle structures (250nm) at 1: 5 weight ratio of siRNA to GC-PEI nanoparticles. In vitro RFP expressing B16F10 tumor cell (RFP/B16F10) culture system, the siRNA-GC-PEI NPs presented a rapid time-dependent cellular uptake profile within 1h. Moreover, the internalized siRNA-GC-PEI NPs lead to specific mRNA breaks down. Furthermore, our new formulation of siRNA-GC-PEI NPs presented a significant inhibition of RFP gene expression of RFP/B16F10-bearing mice, due to their higher tumor-targeting ability. These results revealed the promising potential of GC-PEI NPs as a stable and effective nano-sized siRNA delivery system for cancer treatment. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20184928     DOI: 10.1016/j.jconrel.2010.02.023

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  25 in total

1.  Poly-L-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: its application for head and neck cancer treatment.

Authors:  Hyun-Jong Cho; Saeho Chong; Suk-Jae Chung; Chang-Koo Shim; Dae-Duk Kim
Journal:  Pharm Res       Date:  2011-12-15       Impact factor: 4.200

Review 2.  Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives.

Authors:  Ki Young Choi; Gang Liu; Seulki Lee; Xiaoyuan Chen
Journal:  Nanoscale       Date:  2011-12-01       Impact factor: 7.790

3.  FUNCTIONAL NANOPARTICLES FOR MOLECULAR IMAGING GUIDED GENE DELIVERY.

Authors:  Gang Liu; Magdalena Swierczewska; Seulki Lee; Xiaoyuan Chen
Journal:  Nano Today       Date:  2010-12-01       Impact factor: 20.722

Review 4.  Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.

Authors:  Alicia Fernandez-Fernandez; Romila Manchanda; Anthony J McGoron
Journal:  Appl Biochem Biotechnol       Date:  2011-09-27       Impact factor: 2.926

5.  Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo.

Authors:  S-T Chou; Q Leng; P Scaria; M Woodle; A J Mixson
Journal:  Cancer Gene Ther       Date:  2011-08-05       Impact factor: 5.987

Review 6.  Image-guided nanosystems for targeted delivery in cancer therapy.

Authors:  A K Iyer; J He; M M Amiji
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 7.  Nanovector delivery of siRNA for cancer therapy.

Authors:  H Shen; T Sun; M Ferrari
Journal:  Cancer Gene Ther       Date:  2012-05-04       Impact factor: 5.987

8.  Effects of CD25siRNA gene transfer on high-risk rat corneal graft rejection.

Authors:  Qin Qin; Yunjie Shi; Qingqing Zhao; Dan Luo; Yuan Chen; Jing Wu; Min Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-31       Impact factor: 3.117

9.  Nanoparticles of deoxycholic acid, polyethylene glycol and folic acid-modified chitosan for targeted delivery of doxorubicin.

Authors:  Zhonggen Shi; Rui Guo; Weichang Li; Yi Zhang; Wei Xue; Yu Tang; Yuanming Zhang
Journal:  J Mater Sci Mater Med       Date:  2013-12-11       Impact factor: 3.896

10.  Biocompatible glycol chitosan-coated gold nanoparticles for tumor-targeting CT imaging.

Authors:  In-Cheol Sun; Jin Hee Na; Seo Young Jeong; Dong-Eog Kim; Ick Chan Kwon; Kuiwon Choi; Cheol-Hee Ahn; Kwangmeyung Kim
Journal:  Pharm Res       Date:  2013-08-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.